StockData

Vyome vs Incannex Healthcare

HIND and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIND and IXHL compare

Incannex Healthcare is the larger company, worth 2.2 times as much as Vyome ($24.7M against $11.1M).

Incannex Healthcare scores higher on the StockData Score (7 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHINDIXHL
Size and price
Market cap$11.1M$24.7M
Share price$1.58$1.97
Change, 1 year−70.3%−82.4%
Change, 5 years−100.0%–
Beta (5Y)1.561.95
Employees1812
StockData Score
Total score17 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S72.4×–
P/B–0.4×
FCF yield–−52.1%
Growth
Revenue growth (TTM)−55.6%–
Revenue growth, 5Y average−51.0%–
Profitability
Gross margin50.4%–
Operating margin−2854%–
Net margin−2456%–
Return on equity−149%−47.8% (better)
Financial health
Debt / equity–0.00
Interest coverage−229.3×–
Current ratio3.6848.81 (better)
Altman Z-score−12.31−0.62 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield−53.1% (better)−280%
Shareholder yield−53.1% (better)−280%
Ownership
Held by institutions2.0%3.6%
Held by insiders6.8%–
Short interest, % of float0.28%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.